News and Trends 5 Aug 2022Beyond Biotech podcast 8: Biotech Growth Trust, Deep Science Ventures, Endogena Therapeutics, eureKARE This week’s podcast guests are Laura Fletcher, head of business development and strategic partnerships at Deep Science Ventures; Matthias Steger, CEO of Endogena Therapeutics; Rodolphe Besserve, CEO, and Georges Rawadi, chief of biotech studio development, at eureKARE; and Biotech Growth Trust portfolio manager, Geoff Hsu. Endogena Therapeutics to start clinical stage with treatment for blindness […] August 5, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 5 Aug 2022 Abivax has approval granted to enroll ulcerative colitis patients in two studies Patients with moderate to severe ulcerative colitis (UC) can now be enrolled onto two phase 3 induction studies for a biotech company’s lead candidate drug. France-based Abivax SA is a phase 3 clinical stage biotech company that focuses on developing therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer. […] August 5, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 Immunis closes $10M financing round Immunis Inc., a private U.S. biotech company developing a novel treatment for age and disease-related immune decline, has closed a $10 million series A first closing financing led by Remiges Ventures with participation by several other healthcare investment firms. Proceeds will support clinical assessment of Immunis’ immunomodulatory secretome product in an FDA-awarded phase 1/2a clinical […] August 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 First of its kind drug, to reverse effects of cocaine intoxication, awarded grant An enzyme that efficiently degrades and metabolizes cocaine has been given a ‘cooperative agreement grant’ from the National Institute on Drug Abuse (NIDA) part of the National Institutes of Health. The recombinant enzyme is a double-mutant cocaine esterase 200 mg intravenous (IV) solution and treats cocaine intoxication, which refers to the state of when cocaine […] August 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 Deal worth $3.7B sealed as Amgen buys biopharma ChemoCentryx A company producing drugs including TAVNEOS to treat autoimmune diseases, plus others dealing with inflammatory disorders and cancer has been bought by biopharmaceutical company, Amgen for $52 per share. ChemoCentryx and Amgen have entered a definitive agreement worth approximately $3.7 billion. Robert Bradway, chairman and chief executive officer at Amgen, said: “The acquisition of ChemoCentryx […] August 4, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 Novavax starts COVID-19 vaccine trial for children aged six months to 11 years U.S. biotech company Novavax, Inc., has started its phase 2b/3 Hummingbird global clinical trial. The trial will evaluate the safety, effectiveness (immunogenicity), and efficacy of two doses of the Novavax COVID-19 vaccine (NVX-CoV2373) in younger children aged six months through 11 years, followed by a booster at six months after the primary vaccination series. “We […] August 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 Gilead Sciences set to acquire MiroBio for $405M California-headquartered Gilead Sciences, Inc. and MiroBio, a privately-held U.K.-based biotech company, have announced the companies have entered into a definitive agreement with Gilead acquiring MiroBio for approximately $405 million in cash, subject to customary adjustments. The acquisition will provide Gilead with MiroBio’s discovery platform and entire portfolio of immune inhibitory receptor agonists. MiroBio’s lead investigational […] August 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Aug 2022 RoslinCT and Lykan Bioscience combine to create cell therapy CDMO RoslinCT, a cell and gene therapy contract development and manufacturing organization (CDMO) developing life-changing therapies in Edinburgh’s BioQuarter, and Lykan Bioscience, a CDMO focused on cell-based therapies, have entered into a business combination agreement to form a global advanced therapies CDMO. The combined group will offer process development expertise and cGMP manufacturing for a range […] August 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 The eyes have it – Visiox Pharma closes $7M seed round Visiox Pharma, LLC, a privately-funded U.S. biopharmaceutical company focused on the development and commercialization of ophthalmic drugs to address highly prevalent diseases in need of new treatment options, has announced the closing of a $7 million seed round of financing. The raise was funded by the Founding Partners and a group of ophthalmic industry leaders. […] August 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 Allarity Therapeutics drug no longer commercially viable or in shareholders’ best interest Allarity Therapeutics, after meeting with the US Food and Drug Administration (FDA), has decided a growth factor receptor drug it licensed from Novartis is no longer commercially viable or in the best interests of its shareholders. A type C advisory meeting was held between Allarity and the FDA to discuss a development path for dovitinib. […] August 3, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 3 Aug 2022 Allarity Therapeutics takes advice from its board and switches focus to combination therapies US-based Allarity Therapeutics has made a decision to change tack and focus on combination therapy approaches while making the most of its current assets. The company says the new strategy, driven by its board of directors, aligns with the ongoing shift in oncology standard-of-care moving away from monotherapies. Instead it will veer towards more promising […] August 3, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 3 Aug 2022 AbCellera and Atlas Venture to collaborate on new company for therapeutic antibody discovery AbCellera and Atlas Venture have announced a multi-target partnership to discover therapeutic antibodies for up to three drug targets that can be developed and commercialized by a stealth-stage Atlas-backed company. The collaboration leverages Atlas’ track record in forming innovative biotech companies, and AbCellera’s ability to quickly deliver lead drug candidates to bring transformational new medicines […] August 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email